ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance

ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the Stocks That Could Mint Millionaires in 2026.

ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance

ADMA Biologics, Inc. markets BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency, and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics.

In earnings for the third quarter of 2025, the firm provided updated guidance, noting that for 2025, total revenue was now expected to be $510 million, up from prior guidance of more than $500 million. The 2025 adjusted net income was also modestly adjusted to $158 million due to a higher effective tax rate.

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term